Ken Griffin Clene Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Clene Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 6,500 shares of CLNN stock, worth $34,450. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,500
Previous 1,500
333.33%
Holding current value
$34,450
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding CLNN
# of Institutions
47Shares Held
6.9MCall Options Held
287KPut Options Held
162K-
Vanguard Group Inc Valley Forge, PA2.62MShares$13.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA922KShares$4.88 Million0.0% of portfolio
-
Lunt Capital Management, Inc. Holladay, UT591KShares$3.13 Million0.1% of portfolio
-
Scoggin Management LP New York, NY375KShares$1.99 Million0.05% of portfolio
-
Morgan Stanley New York, NY339KShares$1.79 Million0.0% of portfolio
About Clene Inc.
- Ticker CLNN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 63,502,000
- Market Cap $337M
- Description
- Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...